VERTEX PHARMACEUTICALS INC / MA Restricted Cash and Cash Equivalents, Current
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Restricted Cash and Cash Equivalents, Current of $8.00 million as of 2019-12-31, per its 10-K filed 2020-02-13.
Discontinued › Balance Sheet › Assets › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue · last filed 2020-02-13
- 2019-12-31: Restricted Cash and Cash Equivalents, Current $8.00M.
- 2018-12-31: Restricted Cash and Cash Equivalents, Current $4.91M.
- 2018-09-30: Restricted Cash and Cash Equivalents, Current $8.14M.
- 2018-06-30: Restricted Cash and Cash Equivalents, Current $8.51M.
| Period end | Restricted Cash and Cash Equivalents, Current | Restricted Cash and Cash Equivalents, Current as first filed |
|---|---|---|
| 2019-12-31 | $8.00M 10-K · filed 2020-02-13 | |
| 2018-12-31 | $4.91M 10-K · filed 2020-02-13 | |
| 2018-09-30 | $8.14M 10-Q · filed 2018-10-25 | |
| 2018-06-30 | $8.51M 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $9.57M 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $2.11M 10-K · filed 2020-02-13 | $1.49M 10-K · filed 2018-02-15 |
| 2017-09-30 | $1.80M 10-Q · filed 2018-10-25 | |
| 2017-06-30 | $64.63M 10-Q · filed 2018-07-26 | |
| 2017-03-31 | $44.56M 10-Q · filed 2018-04-27 | |
| 2016-12-31 | $47.76M 10-K · filed 2020-02-13 | |
| 2016-09-30 | $58.42M 10-Q · filed 2016-10-31 | |
| 2016-06-30 | $70.51M 10-Q · filed 2016-08-01 | |
| 2016-03-31 | $76.27M 10-Q · filed 2016-05-03 | |
| 2015-12-31 | $78.91M 10-K · filed 2017-02-23 | |
| 2015-09-30 | $75.77M 10-Q · filed 2015-10-30 | |
| 2015-06-30 | $88.32M 10-Q · filed 2015-08-04 | |
| 2014-12-31 | $8.42M 10-K · filed 2016-02-16 | |
| 2013-12-31 | $0.00 10-K · filed 2015-02-13 | |
| 2013-09-30 | $51.06M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $58.29M 10-Q · filed 2013-08-02 | |
| 2013-03-31 | $63.01M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $69.98M 10-K · filed 2014-02-11 | |
| 2012-09-30 | $74.95M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $56.02M 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $58.02M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $51.88M 10-K · filed 2013-03-01 | |
| 2011-09-30 | $0.00 10-K · filed 2012-02-22 | $50.58M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $63.10M 10-Q · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |